Lataa...
Leflunomide: mode of action in the treatment of rheumatoid arthritis
Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. In phase II and III clinical trials of active rheumatoid arthritis, leflunomide was shown to improve primary and secondary outcome measures with a satisfactory safety profile. The active metabolite of leflunomide, A77 1726, at low...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2000
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1753034/ https://ncbi.nlm.nih.gov/pubmed/11053058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.59.11.841 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|